Drug Profile
Research programme: protein therapeutics - Haemacure Corporation
Latest Information Update: 07 Feb 2011
Price :
$50
*
At a glance
- Originator Haemacure Corporation
- Class Enzymes; Proteins
- Mechanism of Action Enzyme replacements; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological disorders; Metabolic disorders
Most Recent Events
- 07 Feb 2011 Discontinued for Haematological disorders in Canada (Parenteral)
- 07 Feb 2011 Discontinued for Metabolic disorders in Canada (Parenteral)
- 07 Mar 2008 Protein therapeutics programme is available for licensing (http://www.haemacure.com)